Overriding safety concerns, FDA approves Karyopharm cancer drug
Federal regulators set aside their previous safety and effectiveness concerns and approved a cancer drug from Newton biotech Karyopharm Therapeutics, giving the company its first commercial product.
Karyopharm (Nasdaq: KPTI) will have to launch the drug without Chief Commercial Officer Anand Varadan, however. Varadan resigned from his position this week, according to a federal filing that coincided with the news of the drug approval. He was replaced by Senior Vice President Perry Monaco. Th e company…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Allison DeAngelis Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Health Management | Monaco Health